<DOC>
	<DOCNO>NCT01536951</DOCNO>
	<brief_summary>This 2-part , randomize , subject- investigator-blind study healthy male female . Part A study determine safe tolerable single oral dose LY3009104 yield drug exposures slightly exceed typical exposure anticipate repeated administration efficacious dose patient . The concentration drug blood stream measure information side effect may occur also collect . Part B study evaluate effect LY3009104 electrical activity heart measure electrocardiogram ( ECG ) relation placebo follow single oral dose .</brief_summary>
	<brief_title>A Study LY3009104 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Are overtly healthy male female determine medical history physical examination . Are drug free , disease free , cardiac abnormality . Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator . Have clinically normal screen electrocardiogram ( ECG ) measurable QT interval judge investigator , Part B allow accurate measurement QT interval . Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data . Have abnormality 12lead ECG , opinion investigator , increase risk associate participate study affect confound QTc analysis QTc great 450 msec . Regularly use know drug abuse and/or show positive finding urinary drug screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>